0000000000550074

AUTHOR

Andreas E. Kremer

showing 5 related works from this author

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2…

2019

Norursodeoxycholic acid is an orally administered side chain-shortened homologue of ursodeoxycholic acid that undergoes hepatic enrichment with hepatoprotective, anti-inflammatory, and antifibrotic activity. We assessed the efficacy of two doses of norursodeoxycholic acid versus placebo for the treatment of non-alcoholic fatty liver disease.We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 dose-finding clinical trial in tertiary referral hospitals and medical centres in Austria (n=6) and Germany (n=23) for patients with non-alcoholic fatty liver disease with or without diabetes. Patients with a clinical diagnosis of non-alcoholic fatty liver disease and serum alani…

AdultBlood GlucoseMalemedicine.medical_specialtyCholagogues and CholereticsPopulationPlaceboGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawNon-alcoholic Fatty Liver DiseaseDiabetes mellitusInternal medicinemedicineHumansAspartate Aminotransferaseseducationeducation.field_of_studyHepatologyDose-Response Relationship Drugbusiness.industryFatty liverUrsodeoxycholic AcidGastroenterologyAlanine TransaminaseMiddle Agedmedicine.diseaseLipidsUrsodeoxycholic acidClinical trialDose–response relationshipTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemalebusinessmedicine.drugThe lancet. Gastroenterologyhepatology
researchProduct

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

2021

Background & Aims There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment failure and rescue treatment options in these patients. Methods Samples from 40 patients with HCV genotypes (GT) 1-4 in whom VOX/VEL/SOF retreatment failed were collected within the European Resistance Study Group. Population-based resistance analyses were conducted and clinical parameters and retreatment efficacies were evaluated retrospectively in 22 patients. Results Most VOX/VEL/SOF failure patients were infected with HCV GT3a (n = 18, 45%) or GT1a (n = 11, 28%) and had cirrhosis …

0301 basic medicineHepatitis C Virusmedicine.medical_specialtySofosbuvirVoxilaprevirPopulationresistance-associated substitutionsDirect-acting antiviralVoxilaprevir/velpatasvir/sofosbuvir.GastroenterologySettore MED/07Telaprevir03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVoxilaprevir/Velpatasvir/SofosbuvirInternal medicineBoceprevirRescue therapymedicineResistance-associated substitutioneducationdirect-acting antiviralsDAAeducation.field_of_studyHepatologybusiness.industryvirus diseasesGlecaprevirDAA; HCV; Hepatitis C Virus; Voxilaprevir/Velpatasvir/Sofosbuvir; direct-acting antivirals; rescue therapy; resistance-associated substitutionsdigestive system diseasesPibrentasvirRegimen030104 developmental biologychemistryHCV030211 gastroenterology & hepatologyHepatitis C virubusinessmedicine.drugJournal of Hepatology
researchProduct

S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion

2017

030207 dermatology & venereal diseases03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industry030220 oncology & carcinogenesisMEDLINEMedicineDermatologybusinessDermatologyJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

2022

BACKGROUND & AIMS: Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) has been shown to predict outcomes of patients with primary biliary cholangitis (PBC) in small-size studies. We aimed to validate the prognostic value of LSM in a large cohort study. METHODS: We performed an international, multicentre, retrospective follow-up study of 3,985 patients with PBC seen at 23 centres in 12 countries. Eligibility criteria included at least 1 reliable LSM by VCTE and a follow-up ≥ 1 year. Independent derivation (n = 2,740) and validation (n = 568) cohorts were built. The primary endpoint was time to poor clinical outcomes defined as liver-related complications,…

Liver CirrhosisFibroScan; Mortality; PBC; Prognosis; TransplantationTransplantationHepatologyFibroScanPrognosiLiver Cirrhosis BiliaryLiver CirrhosiPrognosisPBCVibrationFollow-Up StudieCohort StudiesLiverElasticity Imaging TechniqueRetrospective StudieHumansElasticity Imaging TechniquesMortalityCohort StudieRetrospective StudiesFollow-Up StudiesHuman
researchProduct

Erarbeitung eines PBC-Therapiepfads für eine integrierte Versorgung in Deutschland

2019

Zeitschrift für Gastroenterologie
researchProduct